• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Roflumilast Patient Selection for Plaque Psoriasis Treatment


Experts describe roflumilast patient selection for plaque psoriasis treatment.

LindaStein Gold, MD: In terms of patient selection, is there a particular patient with plaque psoriasis who would not be a candidate for either of these?

Jennifer Soung, MD: I can’t think of a patient who wouldn’t be a candidate. It has not been studied to be used with other systemics, but I certainly use it in patients who are already on an oral systemic or a biologic, and who have those residual plaques, or in those areas that are tough to treat or have unique considerations like that genital area. Those are patients who are super thankful, such as the gentleman with the psoriasis in the gluteal fold as well as patients who have it in the genital area, because it changes their lives. These are areas of the skin where it has a disproportionate impact on their quality of life. Even though it’s a small body surface area, it can have a huge impact. Sometimes we forget that. Systemic therapy may not get them as clear as they want to be in these areas, so it’s nice to have both of these topical options.

LindaStein Gold, MD: I agree. The thing we haven’t talked about is patients who have skin color. We have to remember that a potent steroid takes that color out and bleaches it. With both of these new nonsteroidals, you can treat the face and not be left with that hypopigmented patch, which is nice. The problem with super-potent steroids is that they work fast, but it’s always right as they start to kick in that it’s time to stop using them. We don’t have that short duration of treatment. Both studies have been shown to be effective in long-term clinical trials. It simplifies the treatment approach.

We’ve had a great conversation. We have so much to talk about. I’m thrilled that we have these new options. I certainly appreciate your perspective and your experience in educating us on how to get our patients with psoriasis under better control. Our takeaways are that topical therapy remains the mainstay of treatment for our patients with plaque psoriasis. We have new options available. This allows us to enhance their quality of life and our ability to get our patients’ lives under control.

Jennifer, thank you for joining me. Thank you to our audience. We appreciate you joining us for this informative program.

Transcript edited for clarity

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.